X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will fund the preparation of clinical study programs for PUR0110 (thykamine) in phase 2/3 program of pediatric atopic dermatitis, phase 2 programs of radiodermatitis associated with radiotherapy and in Hand and Foot Syndrome and associated with chemotherapy.
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 06, 2023
Details:
The proceeds will fund the clinical study programs for PUR0110 (thykamine) in particular the phase 2/3 program in pediatric atopic dermatitis, the phase 2 programs in radiodermatitis associated with radiotherapy and in Hand and Foot Syndrome and associated with chemotherapy.
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TSX Venture Exchange
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 19, 2023
Details:
Thykamine (PUR0110) is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders.
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
In the study, a significantly greater proportion of adult patients treated with Thykamine™ (PUR0110) cream 0.10% achieved an IGA of clear/almost clear and at least a 2-grade improvement from baseline in IGA (30.8%) compared to placebo (6.7%; P =.014).
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The benefit of PUR0110 (Thykamine) cream 0.10% was supported by a statistically significant effect on the primary and secondary endpoints of Body Surface Area (BSA), pruritis, and Patient-Oriented Eczema Measure score (POEM).
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
According to the results from the study, Thykamine at 0.1% showed significant improvement in skin clearance versus placebo at all measured timelines, thereby meeting the primary endpoint. It showed a fast onset of the therapeutic effect.
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: PurGenesis Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Devonian announced that the US Patent and Trademark Office has issued a Notice of Allowance for patent titled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease" covering the use of Thykamine™ for the treatment of Ulcerative Colitis.
Lead Product(s): Thylakoid extract
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
